by Carolyn Haywood | Nov 1, 2018 | Briefings, EPO
The two patent applications that were the subject of last week’s sequential hearings are both divisional applications of EP2771468 which was revoked in January 2018 and is currently under Appeal at the EPO. The two sequential hearings were consolidated with...
by Juliette Boynton | Oct 1, 2018 | Briefings, UK
Gilead was the owner of an SPC for a combination of two actives, namely tenofovir and emtricitabine, which they market as Truvada®, which Teva and others wished to revoke. Interestingly, Gilead also sells tenofovir alone in the absence of an SPC. In accordance with...
by David Eyre | Sep 1, 2018 | Briefings, Designs & Copyright, Trademarks, UK, UPC
Patents, Supplementary Protection Certificates (SPCs) and the Unitary Patent Court (UPC) Trade Marks and Designs Copyright Exhaustion of Rights Please click on one of the hyperlinks above to go to the particular guidance note. The overarching intention of the...
by David Eyre | Aug 1, 2018 | Briefings, EPO, US & International
What Are GMO and Why Are They Regulated? Genetically modified organisms are heavily regulated in Europe and indeed most of the Western hemisphere. In Europe this is governed by Directive 2001/18/EC on the deliberate release of GMOs into the environment (the “GMO...
by Sean Hughes | Jul 1, 2018 | Briefings, US & International
NDAs A non-disclosure agreement (NDA) is a legal contract between two or more parties that outlines confidential material, knowledge or information that the concerned parties wish to share with one another but wish to restrict access to third parties. Clients often...
Recent Comments